Strategic Acquisition Formedix was acquired by Certara in 2023, integrating its clinical trial solutions into Certara’s specialized portfolio. This presents an opportunity to offer complementary products, integrations, or value-added services that align with Certara’s expanded offerings.

Innovative Partnerships Recent collaborations with OpenClinica and Mednet demonstrate Formedix's focus on automation and interoperability in clinical trials, highlighting potential for selling advanced automation, integration, and data management tools to existing and future clients in healthcare and biotech sectors.

Product Development The launch of the Formedix CORE desktop application indicates an emphasis on supporting industry standards like CDISC CORE, opening doors to target organizations seeking compliant software solutions and offering opportunities for upselling or customization services.

Community Engagement With the creation of the Formedix ryze Community, the company fosters a collaborative ecosystem for customers. This environment offers a platform to cross-sell additional solutions, training, and premium support services to engaged users highly invested in clinical trial software.

Market Position Recognized as a top employer in 2020 and maintaining active industry partnerships, Formedix is positioned as a trusted and innovative player in clinical research technology, making it a compelling partner for organizations seeking reliable, standards-compliant solutions in the clinical trial sector.